Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (979) 979
Book Review (347) 347
Publication (48) 48
Conference Proceeding (12) 12
Book Chapter (7) 7
Magazine Article (6) 6
Book / eBook (3) 3
Newspaper Article (3) 3
Data Set (1) 1
Government Document (1) 1
Newsletter (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (710) 710
index medicus (698) 698
biosimilar pharmaceuticals - therapeutic use (370) 370
biosimilar pharmaceuticals - adverse effects (281) 281
biosimilars (278) 278
biosimilar (277) 277
pharmacology & pharmacy (254) 254
biological products (231) 231
safety (219) 219
female (204) 204
male (194) 194
oncology (186) 186
adult (179) 179
middle aged (161) 161
biosimilar pharmaceuticals (155) 155
immunogenicity (146) 146
treatment outcome (146) 146
double-blind (138) 138
efficacy (132) 132
biosimilar pharmaceuticals - administration & dosage (131) 131
infliximab (125) 125
drug approval (122) 122
animals (119) 119
therapeutic equivalency (118) 118
rheumatology (116) 116
medicine & public health (105) 105
united states (100) 100
antibodies (98) 98
biosimilar pharmaceuticals - pharmacokinetics (97) 97
clinical trials (94) 94
analysis (93) 93
monoclonal antibodies (93) 93
pharmaceutical industry (93) 93
aged (92) 92
antibodies, monoclonal - therapeutic use (90) 90
patients (88) 88
pharmacokinetics (87) 87
biosimilar pharmaceuticals - economics (84) 84
medicine, research & experimental (84) 84
rheumatoid arthritis (84) 84
fda approval (82) 82
europe (81) 81
innovator infliximab (81) 81
pharmacology (81) 81
drugs (79) 79
parallel-group (78) 78
chemotherapy (76) 76
young adult (76) 76
biosimilar pharmaceuticals - pharmacology (75) 75
pharmacovigilance (75) 75
ct-p13 (74) 74
biotechnology & applied microbiology (73) 73
studies (73) 73
cancer (72) 72
care and treatment (70) 70
immunology (70) 70
generic drugs (69) 69
review (68) 68
arthritis (66) 66
research (66) 66
antirheumatic agents - therapeutic use (65) 65
rheumatoid-arthritis (64) 64
double-blind method (63) 63
arthritis, rheumatoid - drug therapy (62) 62
drug therapy (62) 62
infliximab - therapeutic use (62) 62
proteins (62) 62
biotechnology (61) 61
usage (61) 61
biologics (59) 59
biomedicine (59) 59
internal medicine (58) 58
biopharmaceuticals (57) 57
manufacturing (57) 57
medicine (57) 57
therapy (57) 57
filgrastim (56) 56
hematology (56) 56
biological products - therapeutic use (55) 55
cancer research (54) 54
colony-stimulating factor (54) 54
interchangeability (54) 54
pharmacotherapy (53) 53
european union (52) 52
anemia (50) 50
biosimilar pharmaceuticals - standards (50) 50
pharmacology/toxicology (50) 50
comparability (49) 49
inflammatory bowel disease (49) 49
adolescent (48) 48
inflammatory bowel diseases - drug therapy (48) 48
medicine, general & internal (48) 48
neoplasms - drug therapy (48) 48
antirheumatic agents - adverse effects (47) 47
red-cell aplasia (47) 47
tumor necrosis factor-alpha - antagonists & inhibitors (47) 47
drug substitution (46) 46
extrapolation (46) 46
united states food and drug administration (46) 46
dosage and administration (45) 45
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (973) 973
German (13) 13
French (6) 6
Spanish (4) 4
Italian (2) 2
Russian (2) 2
Dutch (1) 1
Icelandic (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)–Positive Metastatic Breast Cancer: A Randomized Clinical Trial
by Rugo, Hope S and Barve, Abhijit and Waller, Cornelius F and Hernandez-Bronchud, Miguel and Herson, Jay and Yuan, Jinyu and Sharma, Rajiv and Baczkowski, Mark and Kothekar, Mudgal and Loganathan, Subramanian and Manikhas, Alexey and Bondarenko, Igor and Mukhametshina, Guzel and Nemsadze, Gia and Parra, Joseph D and Abesamis-Tiambeng, Maria Luisa T and Baramidze, Kakhaber and Akewanlop, Charuwan and Vynnychenko, Ihor and Sriuranpong, Virote and Mamillapalli, Gopichand and Ray, Sirshendu and Yanez Ruiz, Eduardo P and Pennella, Eduardo and Heritage Study Investigators and for the Heritage Study Investigators
JAMA, ISSN 0098-7484, 01/2017, Volume 317, Issue 1, pp. 37 - 47
IMPORTANCE: Treatment with the anti-ERBB2 humanized monoclonal antibody trastuzumab and chemotherapy significantly improves outcome in patients with ERBB2... 
ADJUVANT CHEMOTHERAPY | MEDICINE, GENERAL & INTERNAL | PHASE-II TRIAL | THERAPY | DOCETAXEL | PLUS | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents - therapeutic use | Taxoids - therapeutic use | Breast Neoplasms - chemistry | Time Factors | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Antineoplastic Agents, Phytogenic - therapeutic use | Taxoids - adverse effects | Antineoplastic Agents, Phytogenic - adverse effects | Biosimilar Pharmaceuticals - therapeutic use | Trastuzumab - therapeutic use | Double-Blind Method | Antineoplastic Agents - immunology | Paclitaxel - adverse effects | Trastuzumab - adverse effects | Breast Neoplasms - drug therapy | Paclitaxel - therapeutic use | Remission Induction | Disease Progression | Biosimilar Pharmaceuticals - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Intention to Treat Analysis | Survival Analysis | Breast Neoplasms - mortality | Aged | Receptor, ErbB-2 | Therapeutic Equipoise | Trastuzumab - immunology | Outcome and process assessment (Health Care) | Care and treatment | Breast cancer | Health aspects | Analysis | Young women | Patient safety | Oncology | Biological products | Biomedical research | Womens health | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy
by Emery, Paul and Vencovský, Jirí and Sylwestrzak, Anna and Leszczynski, Piotr and Porawska, Wieslawa and Baranauskaite, Asta and Tseluyko, Vira and Zhdan, Vyacheslav M and Stasiuk, Barbara and Milasiene, Roma and Rodriguez, Aaron Alejandro Barrera and Cheong, Soo Yeon and Ghil, Jeehoon
Annals of the Rheumatic Diseases, ISSN 0003-4967, 01/2017, Volume 76, Issue 1, pp. 51 - 57
Objectives To compare the efficacy and safety of SB4 (an etanercept biosimilar) with reference product etanercept (ETN) in patients with moderate to severe... 
MODERATE | IMMUNOGENICITY | EFFICACY | SAFETY | FC FUSION PROTEIN | SULFASALAZINE | RECEPTOR | RHEUMATOLOGY | COMBINATION | Biosimilar Pharmaceuticals - therapeutic use | Etanercept - adverse effects | Double-Blind Method | Humans | Middle Aged | Antirheumatic Agents - immunology | Male | Treatment Outcome | Methotrexate - therapeutic use | Biosimilar Pharmaceuticals - adverse effects | Arthritis, Rheumatoid - drug therapy | Etanercept - pharmacokinetics | Etanercept - immunology | Antirheumatic Agents - adverse effects | Biosimilar Pharmaceuticals - pharmacokinetics | Adult | Antibodies - blood | Antirheumatic Agents - pharmacokinetics | Female | Aged | Antirheumatic Agents - therapeutic use | Etanercept - therapeutic use | Therapeutic Equivalency | Treatment outcome | Usage | Care and treatment | Safety and security measures | Etanercept | Rheumatoid arthritis | Analysis | Dosage and administration | Methotrexate | Index Medicus | Anti-TNF | DMARDs (biologic) | Clinical and Epidemiological Research | Rheumatoid Arthritis | 1507 | 1506
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study
by Park, Won and Yoo, Dae Hyun and Jaworski, Janusz and Brzezicki, Jan and Gnylorybov, Andriy and Kadinov, Vladimir and Sariego, Irmgadt Goecke and Abud-Mendoza, Carlos and Escalante, William Jose Otero and Kang, Seong Wook and Andersone, Daina and Blanco, Francisco and Hong, Seung Suh and Lee, Sun Hee and Braun, Jürgen
Arthritis Research and Therapy, ISSN 1478-6354, 01/2016, Volume 18, Issue 1, pp. 25 - 25
Background: CT-P13 (Remsima (R), Inflectra (R)) is a biosimilar of the infliximab reference product (RP; Remicade (R)) and is approved in Europe and elsewhere,... 
Immunogenicity | Infliximab | Clinical trial | Efficacy | ASAS | Safety | CT-P13 | Pharmacokinetics | Ankylosing spondylitis | Biosimilar | MULTICENTER | INNOVATOR INFLIXIMAB | ACTIVE RHEUMATOID-ARTHRITIS | METHOTREXATE | MONOCLONAL-ANTIBODY | RHEUMATOLOGY | 2010 UPDATE | SPONDYLOARTHRITIS | RECOMMENDATIONS | DOUBLE-BLIND | PLACEBO-CONTROLLED TRIAL | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Infliximab - therapeutic use | Infliximab - pharmacokinetics | Young Adult | Infliximab - adverse effects | Antirheumatic Agents - adverse effects | Biosimilar Pharmaceuticals - pharmacokinetics | Adult | Female | Neutropenia - chemically induced | Antirheumatic Agents - therapeutic use | Biosimilar Pharmaceuticals - therapeutic use | Double-Blind Method | Spondylitis, Ankylosing - drug therapy | Antibodies, Monoclonal - pharmacokinetics | Treatment Outcome | Spondylitis, Ankylosing - metabolism | Biosimilar Pharmaceuticals - adverse effects | Self Report - standards | Spondylitis, Ankylosing - diagnosis | Internationality | Adolescent | Antirheumatic Agents - pharmacokinetics | Aged | Chemical and Drug Induced Liver Injury | Longitudinal Studies | Complications and side effects | Usage | Patient outcomes | Outcome and process assessment (Health Care) | Dosage and administration | Research | Drug therapy | Methods | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Interchangeability of Biosimilars: A European Perspective
by Kurki, Pekka and van Aerts, Leon and Wolff-Holz, Elena and Giezen, Thijs and Skibeli, Venke and Weise, Martina
BioDrugs, ISSN 1173-8804, 4/2017, Volume 31, Issue 2, pp. 83 - 91
Many of the best-selling ‘blockbuster’ biological medicinal products are, or will soon be, facing competition from similar biological medicinal products... 
Antibodies | Pharmacotherapy | Cancer Research | Molecular Medicine | Biomedicine | DRUG | EFFICACY | SAFETY | IMMUNOLOGY | HEMOPHILIA | IMMUNOGENICITY | THERAPY | ONCOLOGY | PHARMACOLOGY & PHARMACY | MONOCLONAL-ANTIBODIES | INFLIXIMAB | CT-P13 | ORIGINATOR | Etanercept - adverse effects | Filgrastim - adverse effects | Epoetin Alfa - adverse effects | Humans | Antibodies, Monoclonal - adverse effects | Human Growth Hormone - adverse effects | Adalimumab - adverse effects | Biosimilar Pharmaceuticals - adverse effects | Adalimumab - therapeutic use | Drug Industry - methods | European Union | Immune System - drug effects | Biosimilar Pharmaceuticals - pharmacokinetics | Etanercept - therapeutic use | Competition | Biotechnology | Biological products | Legislation | Switches | Arthritis | Patients | Insulin | Switching | Proteins | Medicine | Immunogenicity | Gastroenterology | Manufacturing | Product safety | Drug stores | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text The EGALITY study: a confirmatory, randomized, double‐blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate‐to‐severe chronic plaque‐type psoriasis
by Griffiths, C.E.M and Thaçi, D and Gerdes, S and Arenberger, P and Pulka, G and Kingo, K and Weglowska, J and Hattebuhr, N and Poetzl, J and Woehling, H and Wuerth, G and Afonso, M and EGALITY Study Grp and EGALITY study group and the EGALITY study group
British Journal of Dermatology, ISSN 0007-0963, 04/2017, Volume 176, Issue 4, pp. 928 - 938
What's already known about this topic? Etanercept is a tumour necrosis factor inhibitor successfully used in clinical practice for the treatment of various... 
SECUKINUMAB | SIMILARITY | ARTHRITIS | TNF | CLINICAL-TRIALS | DERMATOLOGY | Etanercept - adverse effects | Psoriasis - drug therapy | Biosimilar Pharmaceuticals - administration & dosage | Double-Blind Method | Drug Administration Schedule | Etanercept - administration & dosage | Humans | Antibodies, Neutralizing - metabolism | Male | Treatment Outcome | Biosimilar Pharmaceuticals - adverse effects | Etanercept - pharmacokinetics | Injections, Subcutaneous | Biosimilar Pharmaceuticals - pharmacokinetics | Adult | Female | Drug Substitution | Chronic Disease | Psoriasis | Etanercept | Care and treatment | Immunogenicity | Tumor necrosis factor | Clinical trials | Antibodies | Data processing | Inflammatory diseases | Tumors | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy
by Choe, Jung-Yoon and Prodanovic, Nenad and Niebrzydowski, Jaroslaw and Staykov, Ivan and Dokoupilova, Eva and Baranauskaite, Asta and Yatsyshyn, Roman and Mekic, Mevludin and Porawska, Wieskawa and Ciferska, Hana and Jedrychowicz-Rosiak, Krystyna and Zielinska, Agnieszka and Choi, Jasmine and Rho, Young Hee and Smolen, Josef S
Annals of the Rheumatic Diseases, ISSN 0003-4967, 01/2017, Volume 76, Issue 1, pp. 58 - 64
Objectives To compare the efficacy, safety, immunogenicity and pharmacokinetics (PK) of SB2 to the infliximab reference product (INF) in patients with moderate... 
ANTIBODIES | RISKS | PLACEBO | MULTICENTER | INNOVATOR INFLIXIMAB | EFFICACY | SAFETY | PARALLEL-GROUP | AMERICAN-COLLEGE | RHEUMATOLOGY | CT-P13 | Severity of Illness Index | Biosimilar Pharmaceuticals - therapeutic use | Double-Blind Method | Humans | Middle Aged | Male | Treatment Outcome | Methotrexate - therapeutic use | Infliximab - immunology | Infliximab - therapeutic use | Infliximab - pharmacokinetics | Biosimilar Pharmaceuticals - adverse effects | Infliximab - adverse effects | Arthritis, Rheumatoid - drug therapy | Antirheumatic Agents - adverse effects | Biosimilar Pharmaceuticals - pharmacokinetics | Adult | Antibodies - blood | Antirheumatic Agents - pharmacokinetics | Female | Aged | Antirheumatic Agents - therapeutic use | Therapeutic Equivalency | Viral antibodies | Treatment outcome | Care and treatment | Usage | Rheumatoid arthritis | Analysis | Antibodies | Dosage and administration | Methotrexate | Biological products | Tuberculosis | Tumor necrosis factor-TNF | Family medical history | Drug dosages | Sedimentation & deposition | Index Medicus | Anti-TNF | DMARDs (biologic) | Disease Activity | Clinical and Epidemiological Research | Rheumatoid Arthritis | 1506
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Phase III, randomized, double-blind study comparing the efficacy, safety, and immunogenicity of SB3 (trastuzumab biosimilar) and reference trastuzumab in patients treated with neoadjuvant therapy for human epidermal growth factor receptor 2-positive early breast cancer
by Pivot, Xavier and Bondarenko, Igor and Nowecki, Zbigniew and Dvorkin, Mikhail and Trishkina, Ekaterina and Ahn, Jin-Hee and Vinnyk, Yuriy and Im, Seock-Ah and Sarosiek, Tomasz and Chatterjee, Sanjoy and Wojtukiewicz, Marek Z and Moiseyenko, Vladimir and Shparyk, Yaroslav and Bello, Maximino and Semiglazov, Vladimir and Song, Sujeong and Lim, Jaeyun
Journal of Clinical Oncology, ISSN 0732-183X, 04/2018, Volume 36, Issue 10, pp. 968 - 974
PurposeThis phase III study compared SB3, a trastuzumab (TRZ) biosimilar, with reference TRZ in patients with human epidermal growth factor receptor 2-positive... 
MULTICENTER | EPIRUBICIN | ONCOLOGY | CONTROLLED SUPERIORITY TRIAL | FOLLOW-UP | OPEN-LABEL | PERTUZUMAB | PLUS TRASTUZUMAB | CHEMOTHERAPY | ADJUVANT TRASTUZUMAB | PACLITAXEL | Breast Neoplasms - surgery | Cyclophosphamide - administration & dosage | Docetaxel - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Epirubicin - administration & dosage | Cyclophosphamide - adverse effects | Young Adult | Breast Neoplasms - enzymology | Docetaxel - administration & dosage | Fluorouracil - administration & dosage | Fluorouracil - adverse effects | Adult | Female | Neoadjuvant Therapy | Chemotherapy, Adjuvant | Receptor, ErbB-2 - biosynthesis | Biosimilar Pharmaceuticals - administration & dosage | Double-Blind Method | Trastuzumab - adverse effects | Trastuzumab - administration & dosage | Breast Neoplasms - drug therapy | Biosimilar Pharmaceuticals - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Aged | Epirubicin - adverse effects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Long-Term Clinical Outcomes After Switching from Remicade® to Biosimilar CT-P13 in Inflammatory Bowel Disease
by Smits, Lisa J. T and Grelack, Anna and Derikx, Lauranne A. A. P and de Jong, Dirk J and van Esch, Aura A. J and Boshuizen, Ronald S and Drenth, Joost P. H and Hoentjen, Frank
Digestive Diseases and Sciences, ISSN 0163-2116, 11/2017, Volume 62, Issue 11, pp. 3117 - 3122
Limited data are available on long-term clinical outcomes regarding the switch from Remicade® to the infliximab biosimilar CT-P13 in inflammatory bowel disease... 
Biochemistry, general | Inflammatory bowel diseases | Disease activity | Medicine & Public Health | Infliximab | Switch | Immunogenicity | Hepatology | Gastroenterology | Biosimilar pharmaceuticals | Oncology | Transplant Surgery | ANTIBODIES | TRIAL | SINGLE-CENTER COHORT | CROHNS-DISEASE | GASTROENTEROLOGY & HEPATOLOGY | ORIGINATOR | Prospective Studies | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Gastrointestinal Agents - administration & dosage | Male | Colitis, Ulcerative - immunology | Infliximab - administration & dosage | Feasibility Studies | Young Adult | Infliximab - adverse effects | Netherlands | Crohn Disease - diagnosis | Tumor Necrosis Factor-alpha - immunology | Biosimilar Pharmaceuticals - pharmacokinetics | Adult | Female | Colitis, Ulcerative - drug therapy | Gastrointestinal Agents - pharmacokinetics | Biosimilar Pharmaceuticals - administration & dosage | Antibodies, Monoclonal - pharmacokinetics | Treatment Outcome | Crohn Disease - immunology | Biosimilar Pharmaceuticals - adverse effects | Colitis, Ulcerative - diagnosis | Antibodies, Monoclonal - administration & dosage | Crohn Disease - drug therapy | Adolescent | Aged | Gastrointestinal Agents - adverse effects | Drug Substitution | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Therapeutic Equivalency | Index Medicus | Abridged Index Medicus | Original
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study
by Cohen, Stanley and Genovese, Mark C and Choy, Ernest and Perez-Ruiz, Fernando and Matsumoto, Alan and Pavelka, Karel and Pablos, Jose L and Rizzo, Warren and Hrycaj, Pawel and Zhang, Nan and Shergy, William and Kaur, Primal
Annals of the Rheumatic Diseases, ISSN 0003-4967, 10/2017, Volume 76, Issue 10, pp. 1679 - 1687
ObjectivesABP 501 is a Food and Drug Administration-approved biosimilar to adalimumab; structural, functional and pharmacokinetic evaluations have shown that... 
TRIAL | METHOTREXATE | MULTICENTER | THERAPY | RHEUMATOLOGY | SIMILARITY | Severity of Illness Index | Biosimilar Pharmaceuticals - therapeutic use | Double-Blind Method | Arthritis, Rheumatoid - blood | Humans | Middle Aged | Male | Adalimumab - adverse effects | Biosimilar Pharmaceuticals - adverse effects | Young Adult | Adalimumab - therapeutic use | C-Reactive Protein - metabolism | Arthritis, Rheumatoid - drug therapy | Aged, 80 and over | Antirheumatic Agents - adverse effects | Biosimilar Pharmaceuticals - pharmacokinetics | Adult | Antibodies - blood | Antirheumatic Agents - pharmacokinetics | Female | Aged | Antirheumatic Agents - therapeutic use | Therapeutic Equivalency | Care and treatment | Safety and security measures | Analysis | Rheumatoid arthritis | Dosage and administration | Adalimumab | Pharmacokinetics | Biological products | C-reactive protein | Psoriasis | Disease | Rheumatology | Clinical trials | FDA approval | Patients | Proteins | Prescription drugs | Immunogenicity | Monoclonal antibodies | Tumor necrosis factor-TNF | Product development | Libraries | Methotrexate | Drug dosages | Food | Structure-function relationships | Index Medicus | DMARDs (biologic) | Clinical and Epidemiological Research | TNF-alpha | inflammation | 2311 | 1506 | rheumatoid arthritis | anti-TNF
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breast cancer
by Lammers, Philip E and Dank, Magdolna and Masetti, Riccardo and Abbas, Richat and Hilton, Fiona and Coppola, Jennifer and Jacobs, Ira
British Journal of Cancer, ISSN 0007-0920, 08/2018, Volume 119, Issue 3, pp. 266 - 273
BACKGROUND: This randomised, double-blind study compared pharmacokinetics, efficacy, safety and immunogenicity of PF-05280014 (potential trastuzumab... 
ADJUVANT CHEMOTHERAPY | MULTICENTER | ONCOGENE | AMPLIFICATION | THERAPY | ONCOLOGY | RANDOMIZED-TRIAL | PHASE-3 | HER2-POSITIVE BREAST-CANCER | PLUS | Antibodies, Monoclonal, Humanized - adverse effects | Breast Neoplasms - surgery | Biosimilar Pharmaceuticals - administration & dosage | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Trastuzumab - adverse effects | Biosimilar Pharmaceuticals - blood | Trastuzumab - administration & dosage | Breast Neoplasms - drug therapy | Trastuzumab - blood | Biosimilar Pharmaceuticals - adverse effects | Young Adult | Antibodies, Monoclonal, Humanized - administration & dosage | Breast Neoplasms - genetics | European Union | Neoadjuvant Therapy - adverse effects | Adolescent | Breast Neoplasms - blood | Mastectomy | Adult | Female | Aged | Effectiveness | Breast cancer | Pharmacology | Patients | ErbB-2 protein | Confidence intervals | Chemotherapy | Randomization | Epidermal growth factor | Immunogenicity | Radiology | Carboplatin | Breast | Product safety | Pharmacokinetics | Trastuzumab | Cancer | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text A randomised, single-blind, single-dose, three-arm, parallel-group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP 501 and adalimumab
by Kaur, Primal and Chow, Vincent and Zhang, Nan and Moxness, Michael and Kaliyaperumal, Arunan and Markus, Richard
Annals of the Rheumatic Diseases, ISSN 0003-4967, 03/2017, Volume 76, Issue 3, pp. 526 - 533
ObjectiveTo demonstrate pharmacokinetic (PK) similarity of biosimilar candidate ABP 501 relative to adalimumab reference product from the USA and European... 
Anti-TNF | Pharmacokinetics | TNF-alpha | RHEUMATOID-ARTHRITIS | DISEASES | SERUM | BIOSIMILARS | RHEUMATOLOGY | ANTIDRUG ANTIBODIES | SIMILARITY | INFLIXIMAB | FAILURE | Single-Blind Method | Area Under Curve | United States | Humans | Middle Aged | Antirheumatic Agents - immunology | Male | Healthy Volunteers | Adalimumab - adverse effects | Young Adult | Adalimumab - blood | Adalimumab - pharmacology | Antirheumatic Agents - adverse effects | Biosimilar Pharmaceuticals - pharmacokinetics | Adult | Female | Adalimumab - immunology | Antirheumatic Agents - blood | Europe | Biosimilar Pharmaceuticals - blood | Biosimilar Pharmaceuticals - adverse effects | Adolescent | Antibodies - blood | Antirheumatic Agents - pharmacokinetics | Therapeutic Equivalency | Biosimilar pharmaceuticals | Research | Adalimumab | Index Medicus | Clinical and Epidemiological Research | 1506
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases
by Kay, Jonathan and Schoels, Monika M and Dörner, Thomas and Emery, Paul and Kvien, Tore K and Smolen, Josef S and Breedveld, Ferdinand C and Task Force Use Biosimilars Treat and Task Force on the Use of Biosimilars to Treat Rheumatological Diseases
Annals of the Rheumatic Diseases, ISSN 0003-4967, 02/2018, Volume 77, Issue 2, pp. 165 - 174
The study aimed to develop evidence-based recommendations regarding the evaluation and use of biosimilars to treat rheumatological diseases. The task force... 
treatment | INNOVATOR INFLIXIMAB | Dmards (biologic) | ACTIVE RHEUMATOID-ARTHRITIS | POSITION STATEMENT | NECROSIS-FACTOR ANTAGONISTS | RHEUMATOLOGY | anti-tnf | ABP 501 | INFLAMMATORY-BOWEL-DISEASE | PARALLEL-GROUP | DOUBLE-BLIND | COMPARATIVE PHARMACOKINETICS | MONOCLONAL-ANTIBODIES | Biosimilar Pharmaceuticals - therapeutic use | Rheumatic Diseases - drug therapy | Humans | Evidence-Based Medicine | Consensus | Biosimilar Pharmaceuticals - adverse effects | Practice Guidelines as Topic | Task forces | Biological products | Rheumatology | Rheumatic diseases | Clinical trials | Infections | FDA approval | Inflammatory diseases | Literature reviews | Tuberculosis | Immunogenicity | Rheumatoid arthritis | TNF inhibitors | Tumor necrosis factor-TNF | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights